List of Antara (micronized) drug patents

Antara (Micronized) is owned by Lupin.

Antara (Micronized) contains Fenofibrate.

Antara (Micronized) has a total of 2 drug patents out of which 0 drug patents have expired.

Antara (Micronized) was authorised for market use on 30 November, 2004.

Antara (Micronized) is available in capsule;oral dosage forms.

Antara (Micronized) can be used as treating severe hypertriglyceridemia; treating primary hypercholesterolemia and mixed dyslipidemia, treating primary hypercholesterolemia and mixed dyslipidemia; treating severe hypertriglyceridemia.

The generics of Antara (Micronized) are possible to be released after 31 May, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8026281 LUPIN Treating metabolic syndrome with fenofibrate
Apr, 2025

(2 years from now)

US9314447 LUPIN Reduced dose pharmaceutical compositions of fenofibrate
May, 2033

(10 years from now)

Drugs and Companies using FENOFIBRATE ingredient

Market Authorisation Date: 30 November, 2004

Treatment: Treating severe hypertriglyceridemia; Treating primary hypercholesterolemia and mixed dyslipidemia


How can I launch a generic of ANTARA (MICRONIZED) before it's patent expiration?
More Information on Dosage

ANTARA (MICRONIZED) family patents


United States








900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic